Abivax (LTS:0RA9) ROCE % : 0.00% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abivax ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abivax's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.00%.

Abivax ROCE % Historical Data

The historical data trend for Abivax's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax ROCE % Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-83.45

-60.37

-106.49

-101.82

-93.25

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
ROCE %	Get a 7-Day Free Trial															-129.22	-56.52	-50.64	-126.50	-

Abivax ROCE % Calculation

Abivax's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-163.811	/	( ( (327.062 - 88.115)	+	(205.228 - 92.834) )	/ 2 )
	=	-163.811	/	( (238.947	+	112.394)	/ 2 )
	=	-163.811	/	175.6705
	=	-93.25 %

Abivax's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	0	/	( ( (327.062 - 88.115)	+	(205.228 - 92.834) )	/ 2 )
	=	0	/	( ( 238.947	+	112.394 )	/ 2 )
	=	0	/	175.6705
	=	0.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Abivax (LTS:0RA9) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abivax ROCE % Related Terms

Thank you for viewing the detailed overview of Abivax's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Abivax Headlines

No Headlines